Pure Global
NCT04157127

Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma

Phase I Study of Th-1 Dendritic Cell Immunotherapy in Combination With Standard Chemotherapy for the Adjuvant Treatment of Pancreatic Adenocarcinoma (DECIST)
Baylor College of Medicine·Phase 1·ClinicalTrials.gov·biologicalRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Pancreatic Adenocarcinoma,Pancreatic Cancer
Drug/Device/Intervention
Autologous DC vaccine
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Baylor College of Medicine
Location
Houston,Houston,Houston, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Aug 03, 2020
End date
Nov 01, 2025
Enrollment
43 participants
Primary outcome

MTD of DC Vaccine,Number of participants who experienced Dose Limiting Toxicities (DLTs)

Summary

This is a phase 1, first in man, dose escalation study for safety and feasibility for
 administration of 3 doses of DC vaccine for pancreatic adenocarcinoma.

ICD-10 classifications
Malignant neoplasm of pancreasMalignant neoplasm: Pancreas, unspecifiedMalignant neoplasm: Head of pancreasMalignant neoplasm: Other parts of pancreasMalignant neoplasm: Tail of pancreas
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04157127
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04157127 through Pure Global AI's free database. This Phase 1 trial is sponsored by Baylor College of Medicine and is currently Recruiting. The study focuses on Pancreatic Adenocarcinoma,Pancreatic Cancer. Target enrollment is 43 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.